<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: The benefit of direct, as opposed to calculated, <z:chebi fb="1" ids="47774">low density lipoprotein -cholesterol</z:chebi> (<z:chebi fb="0" ids="47774">LDL-C</z:chebi>) measurement remains unclear </plain></SENT>
<SENT sid="1" pm="."><plain>This study compared the biological variability of direct <z:chebi fb="15" ids="39026">LDL</z:chebi> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2DM) on equivalent doses of the short half-life <z:chebi fb="0" ids="35664">statin</z:chebi>, <z:chebi fb="0" ids="9150">simvastatin</z:chebi> or the longer half-life <z:chebi fb="0" ids="35664">statin</z:chebi>, <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A cross-over study of biological variation of <z:chebi fb="23" ids="18059">lipids</z:chebi> in 26 patients with T2DM taking either <z:chebi fb="0" ids="9150">simvastatin</z:chebi> 40 mg (n = 10) or <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> 10 mg </plain></SENT>
<SENT sid="3" pm="."><plain>After 3 months on one <z:chebi fb="0" ids="35664">statin</z:chebi>, fasting <z:chebi fb="23" ids="18059">lipids</z:chebi> were measured on 10 occasions over a 5-week period </plain></SENT>
<SENT sid="4" pm="."><plain>The same procedure was then followed on the other <z:chebi fb="0" ids="35664">statin</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>The variability of <z:chebi fb="0" ids="47774">LDL-C</z:chebi> was established using a Beckman direct assay </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: As a group, mean <z:chebi fb="15" ids="39026">LDL</z:chebi> was no different between <z:chebi fb="0" ids="35664">statins</z:chebi> (mean +/- s.d.) (1.69 +/- 0.60 mmol/l <z:chebi fb="0" ids="9150">simvastatin</z:chebi> vs. 1.67 +/- 0.60 mmol/l <z:chebi fb="0" ids="39548">atorvastatin</z:chebi>, p = 0.19) </plain></SENT>
<SENT sid="7" pm="."><plain>However, in <z:hpo ids='HP_0000001'>all</z:hpo> patients, the intraindividual biological variability of <z:chebi fb="15" ids="39026">LDL</z:chebi> while taking <z:chebi fb="0" ids="9150">simvastatin</z:chebi> was markedly higher than with <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> (average s.d. = 0.17 mmol /l <z:chebi fb="0" ids="9150">simvastatin</z:chebi> vs. 0.01 mmol/l, p &lt; 0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>Friedewald calculated <z:chebi fb="15" ids="39026">LDL</z:chebi> variability was no different between <z:chebi fb="0" ids="35664">statins</z:chebi> (average s.d. = 0.34 mmol /l <z:chebi fb="0" ids="9150">simvastatin</z:chebi> vs. 0.21 mmol/l <z:chebi fb="0" ids="39548">atorvastatin</z:chebi>, p = 0.19) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: In contrast to calculated values, direct measurement revealed <z:chebi fb="15" ids="39026">LDL</z:chebi> to be much more stable (the s.d. being an order of magnitude) in T2DM patients taking <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> rather than <z:chebi fb="0" ids="9150">simvastatin</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>This means <z:chebi fb="15" ids="39026">LDL</z:chebi> targets can be consistently met with less <z:chebi fb="23" ids="18059">lipid</z:chebi> monitoring using <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> rather than <z:chebi fb="0" ids="9150">simvastatin</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>Direct <z:chebi fb="15" ids="39026">LDL</z:chebi> measurement may therefore have a particular role in monitoring patients on <z:chebi fb="0" ids="35664">statin</z:chebi> treatment </plain></SENT>
</text></document>